Press

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer

Nov 27 • 3 min read

Bright Minds Biosciences (Nasdaq: DRUG | CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022. The Company also announces that Dr. Revati Shreeniwas’ engagement…

Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call

Nov 22 • 4 min read

Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that it has strengthened its leadership team with the hiring of two senior executives. The Company has appointed Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative Health. “We have deepened the expertise of…

KAYA HOLDINGS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)

Nov 22 • 5 min read

Kaya Holdings, Inc is a holding company with more than eight years of operational experience as a vertically integrated legal cannabis enterprise. KAYS is the first U.S. publicly traded company to operate a legal marijuana dispensary, as well as the first to vertically integrate by adding cultivation and manufacturing. The Company produces, distributes, and/or sells a full range…

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

Nov 22 • 1 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022, at 11:00 a.m. ET / 8:00 a.m. PT. The discussion will focus on key takeaways from Numinus’ Q4…

Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction

Nov 22 • 4 min read

Nirvana Life Sciences Inc. (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic and other natural based medicines, including non-addictive chronic pain and relapse preventing pharmaceutical medicines, is pleased to report that it has entered an agreement to acquire the distributor of a leading addictions focused herbal treatment. Nirvana Life Sciences…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435